Open AccessCOVID-19 and liver diseases, what we know so far
Author(s) -
Mohamed Y. ElNaggar,
Ahmed Abomhya,
Ismail Elkhattib,
Nabila Dawoud,
Rajkumar Doshi
Publication year - 2022
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v10.i13.3969
Subject(s) - medicine , pandemic , covid-19 , outbreak , coronavirus , pneumonia , disease , liver disease , intensive care medicine , betacoronavirus , atypical pneumonia , virology , infectious disease (medical specialty)
Coronavirus disease 2019 (COVID-19) pneumonia outbreak started in December 2019. On March 12, 2020, the World Health Organization (WHO) declared that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a pandemic, and as of May 2021, SARS-CoV-2 has infected over 167.3 million patients, including 3.4 million deaths, reported to WHO. In this review, we will focus on the relationship between SARS-CoV-2 infection and the liver. We will discuss how chronic liver diseases affect the COVID-19 disease course and outcomes. We will also discuss the SARS-CoV-2 effects on the liver, mechanisms of acute liver injury, and potential management plans.